Human medicines European public assessment report (EPAR): Nepexto, etanercept, Arthritis, Rheumatoid;Arthritis, Juvenile Rheumatoid;Arthritis, Psoriatic;Spondylarthropathies;Spondylitis, Ankylosing;Psoriasis, Date of authorisation: 20/05/2020, Revision:

Submitted by Anonymous (not verified) on 7 September 2023 - 8:21

Human medicines European public assessment report (EPAR): Nepexto, etanercept, Arthritis, Rheumatoid;Arthritis, Juvenile Rheumatoid;Arthritis, Psoriatic;Spondylarthropathies;Spondylitis, Ankylosing;Psoriasis, Date of authorisation: 20/05/2020, Revision: 10, Status: Authorised

Human medicines European public assessment report (EPAR): Poteligeo, mogamulizumab, Sezary Syndrome;Mycosis Fungoides, Date of authorisation: 22/11/2018, Revision: 6, Status: Authorised

Submitted by Anonymous (not verified) on 6 September 2023 - 14:15

Human medicines European public assessment report (EPAR): Poteligeo, mogamulizumab, Sezary Syndrome;Mycosis Fungoides, Date of authorisation: 22/11/2018, Revision: 6, Status: Authorised

Human medicines European public assessment report (EPAR): Irbesartan Teva, irbesartan, Hypertension, Date of authorisation: 30/10/2009, Revision: 16, Status: Authorised

Submitted by Anonymous (not verified) on 5 September 2023 - 14:53

Human medicines European public assessment report (EPAR): Irbesartan Teva, irbesartan, Hypertension, Date of authorisation: 30/10/2009, Revision: 16, Status: Authorised

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Latest Newsletters

More